Restless leg syndrome manifested by iron deficiency from chronic hemoptysis in cystic fibrosis  by Hayes, Don
Journal of Cystic Fibrosis 6 (2007) 234–236
www.elsevier.com/locate/jcfCase studies
Restless leg syndrome manifested by iron deficiency from chronic
hemoptysis in cystic fibrosis
Don Hayes Jr. ⁎
Departments of Pediatrics and Internal Medicine, University of Kentucky College of Medicine, J410 Kentucky Clinic,
740 South Limestone Street, Lexington, KY 40536
Received 23 September 2005; received in revised form 19 July 2006; accepted 27 July 2006
Available online 18 September 2006Abstract
Restless leg syndrome (RLS) and periodic limb movement disorder (PLMD) are considered to be a continuum of a neurological sleep
disorder associated with abnormal iron metabolism or deficiency. I describe a case of RLS and PLMD in a cystic fibrosis patient with iron
deficiency from chronic hemoptysis. This is the first case that reports RLS and PLMD manifesting from iron deficiency caused by chronic
hemoptysis in advanced cystic fibrosis lung disease.
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Restless leg syndrome (RLS) and periodic limb movement
disorder (PLMD) are closely related disorders that are
considered to be a continuum of the same disorder that can
disturb sleep onset and sleep maintenance. RLS is a clinical
diagnosis during waking hours, and PLMD is a sleep disorder
with clinical symptoms of excessive daytime sleepiness or
insomnia requiring nocturnal polysomnography (NPSG) for
diagnosis. The criteria for diagnosis of RLS include 4 primary
features: (1) unpleasant limb sensations with desire to move
the limbs usually associated with paresthesias/dysesthesias;
(2) motor restlessness, with the patient feeling compelled to
move; (3) symptoms precipitated by rest and relieved by
activity; and (4) symptomsworse in the evening or at night [1].
RLS affects approximately 10% of the population, prevalence
increasing with age [2]. The limb movements of PLMD are
defined as repetitive, stereotypical dorsiflexions of the great
toe with fanning of the small toes accompanied by flexion of⁎ Tel.: +1 859 257 5536; fax: +1 859 257 1888.
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doi:10.1016/j.jcf.2006.07.003the ankle and knee occurring at 5 to 90 second intervals with
duration of 0.5 to 5 s [3]. At least four of these movements
must be present to meet NPSG criteria for a single periodic
limb movement [3]. The International Classification of Sleep
Disorders (ICSD) endorses a grading system for severity of
PLMD: a PLM index of b5/h is considered normal, 5–24/h
mild, 25–49/h moderate, and ≥50/h severe [4]. The ICSD
further reports that the diagnosis of PLMD requires symptoms
of excessive daytime sleepiness and/or insomnia in the
presence of a positive NPSG without evidence of a medical
or psychiatric disorder that could account for complaints [4].
Familial RLS is described with 63% of RLS patients
(n=127) reporting the presence of RLS in at least one of their
first-degree relatives [5]. Patients with hereditary RLS have a
significantly younger age of onset of disease than those with a
negative family history [6]. The pathophysiology of primary
RLS is associated with dopaminergic dysfunction and abnor-
mal brain iron metabolism, and secondary RLS is commonly
associated with iron deficiency [7]. Iron deficiency is a sig-
nificant concern in the cystic fibrosis (CF) population with
progressing lung disease being associated with iron loss in
sputum [8]. Iron deficiency in the CF population is not related
to pancreatic insufficiency or its supplementation [9,10]. Ied by Elsevier B.V. All rights reserved.
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in a CF patient with end stage lung disease and chronic
hemoptysis.
2. Case report
22-year-old male with CF and pancreatic insufficiency
presented to the adult CF clinic for routine care. Due to end
stage lung disease and deteriorating pulmonary function, he
was started on supplemental oxygen at 2 L per minute during
exercise and sleep and was listed for lung transplantation
1 year earlier. For the past 6 years, he had daily cough produc-
tive of green sputum. He developed the onset of small streaks
of blood in his sputum 2 years previous. The hemoptysis
initially occurred monthly; but over the past 6 months, the
frequency of episodes had increased to daily. The volume of
blood loss described as less than a teaspoon per episode had
not changed. His appetite was excellent with supplemental
gastrostomy tube feeds overnight. He denied abdominal pain,
nausea, vomiting, heartburn, gastroesophageal reflux, hema-
temesis, melena, and hematochezia. He denied use of iron
supplements as well as reported that he rarely consumed red
meat. He was diagnosed with depression 1 year previous but
refused medical therapy. For the past 18 months, he had
noticed daytime fatigue and hypersomnolence with progres-
sion of these symptoms over the past 6months. Despite 7 to 8 h
of sleep nightly, he reported awakening with non-restorative
sleep. His wife confirmed that he kicked his legs and jerked his
lower body throughout the night. Further questioning revealed
that he had an occasional urge to move his legs during the day
with worsening of this sensation prior to bedtime leading to
difficulty achieving sleep. This urge to move his lower
extremities was not associated with pain but rather a sensation
of “pins and needles,” with resolution of the symptoms upon
walking. He denied arm involvement but reported that
symptoms occurred in both legs with daytime naps. Kidney
and liver functionwas normal, and screening for cystic fibrosis
related diabetes was unremarkable. He further denied history
of esophageal varices and peripheral neuropathy as well as
family history of RLS/PLMD.
Physical exam of both lower extremities was normal
without skin discolorations or hair loss and normal pulses.
Complete neurological exam was normal with intact gait. His
pulmonary function was at baseline with FVC of 2.27 L (44%
predicted) and FEV [1] of 1.17 L (28% predicted). Chest X-ray
revealed chronic changes related to CF and significant hyper-
inflation. Laboratory findings revealed hemoglobin 14.4 g/dL
(13.6–17.2 g/dL), mean corpuscular volume (MCV) of 79 fL/
RBC (82–97 fL/RBC), iron level of 13μg/dL (50–160μg/dL),
transferrin saturation of 3% (16–50%), and ferritin level of
32 μg/L (20–300 μg/L). Stools were negative for blood. Cell
count of sputum cultures obtained over the past 2 years had
N25 red blood cells/low power field consistent with chronic
blood loss in his sputum confirming his observations of chronic
hemopytsis in his sputum. To assess for PLMD and other sleep
disorders, a NPSG revealed normal sleep and rapid eyemovement (REM) latencies with a significantly reduced sleep
efficiency at 62%. Ten hypopneas lead to an apnea–hypopnea
index of 2.3 events per hour of sleep on supplemental oxygen at
2 L per minute. A total of 93 limb movements met criteria for
PLMD leading to an arousal index of 19 events per hour of
sleep. Supplemental ferrous sulfate of 300 mg orally twice
daily was initiated with continuation of supplemental oxygen.
With the iron supplementation, symptoms of RLS during the
day and PLMD during sleep resolved over the next month
leading to significant improvement in daytime fatigue and
hypersomnolence. At follow up 3months later, his iron indices
had normalized.
3. Discussion
The mechanism of action of primary or idiopathic RLS is
not completely understood; however, a recent study indicates
that RLSmay be due to low brain iron concentration caused by
the dysfunction of iron transportation from serum to the central
nervous system [10]. Several etiologies are associated with
secondary RLS; including iron deficiency, renal failure, neu-
ropathies, myopathies, pregnancy, and drugs (caffeine, sero-
tonin reuptake inhibitors, tricyclic antidepressants, and
dopamine blockers) [1]. The rationale for iron deficiency in-
volvement of these disorders is the need for iron in tyrosine
hydroxylation which is the rate limiting step in the biosyn-
thesis of dopamine. Magnetic resonance imaging (MRI)
techniques have demonstrated decreased iron content in the
nigrostriatal areas in RLS patients [11]. Disease severity
correlates the degree of nigrostriatal iron depletion [11]. Sun
et al. published that RLS is exacerbated with ferritin levels
b50 μg/L [12]. Reduced ferritin and elevated transferrin levels
in cerebrospinal fluid is indicative of low brain iron in patients
with idiopathic RLS [13].
Iron deficiency has been described in the CF population
[8,9,14]. A study of 127 patients revealed 32% having low
serum ferritin concentrations and iron deficiency [14]. Pond
and colleagues reported 62% of adult CF patients (n=71)
had functional iron deficiency defined as transferrin
saturation b16% with 12 patients being anemic (10 with
iron deficiency and 2 with normal iron studies) [9]. Of the 30
randomly selected adult CF patients (median age, 26 years;
range, 21 to 36 years), 74% had iron deficiency defined as
serum iron levels ≤12 μmol/L and/or transferrin saturation
≤16% [6]. In 2002, Reid et al. published that CF patients are
iron deficient due to loss of iron within the airways [8].
Median serum ferritin levels were 39 μg/L with a range from
5 to 440 μg/L with sputum concentrations of iron (median,
63 μmol/L; range, 17 to 134 μmol/L) and ferritin (median,
5038 μg/L; range 894 to 6982 μg/L) [8]. There was a sig-
nificant negative relationship between lung function mea-
sured by FEV[1] percent predicted and sputum iron and
ferritin content [8].
If iron deficiency is not the cause of RLS/PLMD or if
there is no response to iron replacement, commonly used
drug therapies for RLS/PLMD include dopaminergic agents
236 D. Hayes Jr. / Journal of Cystic Fibrosis 6 (2007) 234–236(carbidopa–levodopa), dopamine agonists (pergolide, par-
mipexole, and ropinirole), benzodiazepines, antiepileptics,
and opioids [15]. Treatment should be individualized with
consideration of behavioral therapy if indicated.
4. Conclusion
In addition to iron deficiency, other factors may contribute
to the development of RLS/PLMD as it is clear that not all
patients with iron deficiency develop RLS/PLMD; and con-
versely, this disorder continuummay occur in patients without
iron deficiency. However, iron deficiency is a significant ag-
gravator of this disorder in those patients susceptible for either
genetic or systemic reasons. Advanced CF lung disease is a
risk factor for iron deficiency due poor nutritional status, loss
of blood due to esophageal varices from liver disease if pre-
sent, and iron loss into airway secretions. As their lung disease
progresses, CF patients may suffer from significant fatigue
with advancing lung disease being the most likely etiology;
however, other contributing factors should also be considered.
Physicians should be aware of RLS/PLMD as a potential con-
tributing factor to fatigue and hypersomnolence in this patient
population.
References
[1] Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome:
diagnostic criteria, special considerations, and epidemiology. A report
from the restless legs syndrome diagnosis and epidemiology workshop
at the National Institutes of Health. Sleep Med 2003;4:101–9.[2] Comella CL. Restless legs syndrome: treatment with dopaminergic
agents. Neurology 2002;58:S87–92.
[3] The ASDATask Force. Recording and scoring leg movements. Sleep
1993;16:749–59.
[4] Diagnostic Classification Steering Committee, Thorpy MJ, Chair:
International Classification of Sleep Disorders. Rochester, Minnesota,
American Sleep Disorders Association, 1990.
[5] Montplaisir J, Boucher S, PoirierG, et al. Clinical, polysomnographic, and
genetic characteristics of restless legs syndrome: a study of 133 patients
diagnosed with new standard criteria. Mov Disord 1997;12:61–5.
[6] Winkelmann J, Wetter TC, Collado-Seidel V, et al. Clinical charac-
teristics and frequency of the hereditary restless legs syndrome in a
population of 300 patients. Sleep 2000;23:597–602.
[7] Allen R. Dopamine and iron in the pathophysiology of restless legs
syndrome (RLS). Sleep Med 2004;5:385–91.
[8] Reid DW, Withers NJ, Francis L, et al. Iron deficiency in cystic
fibrosis: relationship to lung disease severity and chronic Pseudomo-
nas aeruginosa infection. Chest 2002;121:48–54.
[9] Pond MN, Morton AM, Conway SP. Functional iron deficiency in
adults with cystic fibrosis. Respir Med 1996;90:409–13.
[10] Mizuno S, Mihara T, Miyaoka T, et al. CSF iron, ferritin and transferrin
levels in restless legs syndrome. J Sleep Res 2005;14:543–7.
[11] Allen RP, Barker PB, Wehrl F, et al. MRI measurement of brain iron in
patients with restless legs syndrome. Neurology 2001;56:263–5.
[12] Sun ER, Chen CA, Ho G, et al. Iron and the restless legs syndrome.
Sleep 1998;21:371–7.
[13] Earley CJ, Connor JR, Beard JL, et al. Abnormalities in CSF
concentrations of ferritin and transferrin in restless legs syndrome.
Neurology 2000;54:1698–700.
[14] Ehrhardt P, Miller MG, Littlewood JM. Iron deficiency in cystic
fibrosis. Arch Dis Child 1987;62:185–7.
[15] Avecillas JF, Golish JA, Giannini C, et al., Restless legs syndrome: keys
to recognition and treatment. Cleve Clin J Med 2005;72:769–70, 773–4,
776 passim.
